CAPE TOWN, SA / ACCESSWIRE / April 14, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
The company is pleased to announce its brand Medspresso™ has partnered with CNC, the preferred food supplier to top chefs, restaurants, and home cooks all across South Africa. CNC’s values of dignity, love and respect for everyone is evident through their admirable Corporate Social Responsibility (CSR) efforts via ‘Souper Troopers’. With their project, The Humanity Hub, they address the holistic needs of human beings, starting with the most basic needs including clothes, food and toiletries and then working through a full range of services such as counselling, skills training, medical referrals, family mediation, job preparation, creative workshops, and micro entrepreneurial opportunities.
CNC now carries the Medspresso™ range alongside its other gourmet products on their e-commerce platform. The new partners are an established and trusted name in food distribution and are built on exceptional customer service and quality products.
Charlene Shapiro, Founder & CEO of CNC said, “It is such a pleasure to form this partnership with a company such as M2Bio Sciences, who value both giving back to communities as well as providing customers with exceptional quality products as much as we do. The Medspresso™ products are fantastic and we are sure that our customers will enjoy them as much as we do. We are glad to have another team to support us in our Souper Troopers mission, together our impact will be immense.”
“The fact that Charlene, Kerry and the team at CNC understand business is not only about making money but also about acting responsibly towards the environment and people who inhabit it made this partnership a no-brainer. We are super excited to begin several CSR activities with them as we, as a company, truly believe in uplifting other people along our journey of growing our Medspresso™ brand.” said Jeff Robinson Wuhan General CEO.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc.
Wuhan General Group, Inc. through its wholly owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™, Liviana™ and Handcrafted Delights™ brands. In addition, its wholly owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
For further information:
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
Kerry Hoffman – Marketing and CSI Co-Ordinator
Charlene Shapiro – Founder & CEO
SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.
View source version on accesswire.com: